SCHEMBL18005192

SCHEMBL18005192

CC(=O)Nc1ccc(Br)c(Cl)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.50
SCN9A Q15858 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
SCN10A Q9Y5Y9 1/20 0.47
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
ADORA3 P0DMS8 1/20 0.42
NPC1 O15118 5/20 0.41
RAB9A P51151 4/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPK8 P45983 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
SORT1 Q99523 1/20 0.40
MAPT P10636 1/20 0.40
CYP1A2 P05177 1/20 0.40
HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16685587 0.80 KDM4E (0.46) PTK2SCN9ASCN2ASCN3ASCN10A
SCHEMBL1269767 0.80 RAB9A (0.60) KDM4ELMNANPC1RAB9AKMT2A
SCHEMBL9143700 0.80 KDM4E (0.46) PTK2SCN9ASCN2ASCN3ASCN10A
SCHEMBL12138429 0.79 MAPK8 (0.45) PTK2SCN9ASCN2ASCN3ASCN10A
SCHEMBL18153016 0.79 PTK2 (0.50) PTK2SCN9ASCN2ASCN3ASCN10A
SCHEMBL31438491 0.79 PTK2 (0.50) PTK2SCN9ASCN2ASCN3ASCN10A
SCHEMBL31627174 0.78 ATR (0.45) SCN9ANPC1RAB9AKMT2AMAPT
SCHEMBL15873962 0.77 KDM4E (0.44) PTK2SCN9ASCN2ASCN3ASCN10A
SCHEMBL29424937 0.77 LMNA (0.51) PTK2KDM4ELMNAADORA3NPC1
SCHEMBL1268686 0.77 LMNA (0.51) PTK2KDM4ELMNAADORA3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3259264-B1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2022-07-27 EP disclosed
US-9981944-B2 GDF-8 inhibitors RIGEL PHARMACEUTICALS, INC (US) 2018-05-29 US disclosed
US-9981944-B2 GDF-8 inhibitors RIGEL PHARMACEUTICALS, INC (US) 2018-05-29 US disclosed
US-9981944-B2 GDF-8 inhibitors RIGEL PHARMACEUTICALS, INC (US) 2018-05-29 US disclosed
EP-3259264-A1 GDF-8 INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2017-12-27 EP disclosed
US-20160264553-A1 GDF-8 Inhibitors MIDCAP FINANCIAL TRUST 2016-09-15 US disclosed
US-20160264553-A1 GDF-8 Inhibitors MIDCAP FINANCIAL TRUST 2016-09-15 US disclosed
US-20160264553-A1 GDF-8 Inhibitors MIDCAP FINANCIAL TRUST 2016-09-15 US disclosed
WO-2016133838-A1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2016-08-25 WO disclosed
WO-2016133838-A1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2016-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264553-A1 GDF-8 Inhibitors CXCL8, MSTN, LGALS8 PTK2 2771/4885SCN9A 1737/4885SCN2A 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.